Afya (NASDAQ:AFYA) VP Sells $236,533.87 in Stock

Afya Limited (NASDAQ:AFYA) VP Lelio De Souza Junior sold 16,279 shares of the business’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $14.53, for a total transaction of $236,533.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Lelio De Souza Junior also recently made the following trade(s):

• On Tuesday, April 7th, Lelio De Souza Junior sold 26,753 shares of Afya stock. The shares were sold at an average price of $14.95, for a total transaction of $399,957.35.

Afya Stock Performance

NASDAQ:AFYA opened at $15.07 on Monday. Afya Limited has a one year low of $13.00 and a one year high of $19.90. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.20 and a current ratio of 2.20. The firm has a market cap of $1.41 billion, a P/E ratio of 10.32, a P/E/G ratio of 0.67 and a beta of 0.48. The firm has a 50-day simple moving average of $14.48 and a 200-day simple moving average of $14.67.

Afya (NASDAQ:AFYA) last posted its quarterly earnings results on Wednesday, March 11th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.36 by $0.05. Afya had a net margin of 20.31% and a return on equity of 18.77%. The business had revenue of $147.08 million during the quarter, compared to analyst estimates of $174.74 million. Equities analysts anticipate that Afya Limited will post 1.52 EPS for the current fiscal year.

Afya Announces Dividend

The firm also recently declared an annual dividend, which was paid on Monday, April 6th. Stockholders of record on Wednesday, March 25th were issued a $0.656 dividend. The ex-dividend date was Wednesday, March 25th. This represents a dividend yield of 433.0%. Afya’s payout ratio is currently 45.21%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Afya in a research report on Wednesday, January 21st. Zacks Research raised shares of Afya from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 7th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $22.00 price objective (down from $24.50) on shares of Afya in a research report on Wednesday, January 7th. Sanford C. Bernstein raised shares of Afya to a “market perform” rating in a research report on Friday, January 16th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $16.00 price objective (down from $18.00) on shares of Afya in a research report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Afya presently has a consensus rating of “Hold” and an average target price of $17.30.

Institutional Trading of Afya

Several large investors have recently bought and sold shares of AFYA. Doma Perpetual Capital Management LLC grew its position in Afya by 50.6% during the 3rd quarter. Doma Perpetual Capital Management LLC now owns 891,639 shares of the company’s stock worth $13,910,000 after purchasing an additional 299,419 shares during the last quarter. SPX Gestao de Recursos Ltda purchased a new stake in Afya during the 3rd quarter worth approximately $2,895,000. Swedbank AB grew its position in Afya by 170.3% during the 4th quarter. Swedbank AB now owns 189,200 shares of the company’s stock worth $2,916,000 after purchasing an additional 119,200 shares during the last quarter. Jump Financial LLC purchased a new stake in Afya during the 2nd quarter worth approximately $731,000. Finally, Qube Research & Technologies Ltd purchased a new stake in Afya during the 3rd quarter worth approximately $610,000. Hedge funds and other institutional investors own 88.02% of the company’s stock.

Trending Headlines about Afya

Here are the key news stories impacting Afya this week:

• Positive Sentiment: Short interest fell materially in March — short interest declined about 14.1% to 541,994 shares as of March 31, leaving only ~0.6% of float shorted and a days-to-cover of ~4.4. Lower short interest reduces short pressure and can support upside or limit downside volatility.
• Positive Sentiment: Zacks upgraded Afya from “hold” to “strong-buy”, giving institutional and retail investors a fresh buy-side signal that can attract flows. Zacks upgrade
• Positive Sentiment: The company paid an annual dividend on April 6 ($0.656 per share). The payout returns cash to shareholders and can support investor demand, particularly for income-oriented holders. MarketBeat dividend/coverage
• Neutral Sentiment: Institutional activity: several funds established or increased positions in Q4 (State Street, XTX Topco, Mangrove Partners, etc.). High institutional ownership (~88%) can stabilize stock but also concentrate flows. MarketBeat institutional holdings
• Negative Sentiment: Large insider sale by VP Lelio De Souza Junior — sold 26,753 shares (~$400k) on April 7, reducing his stake by ~62%. Large insider reductions can be perceived negatively by investors and may weigh on near-term sentiment. SEC filing – De Souza Jr sale
• Negative Sentiment: Smaller insider sale by VP De Sousa Anibal Jose Grifo — sold 5,000 shares (~$76k) on April 7 (10% reduction in his position). While smaller than the other sale, it adds to insider-decrease headlines. InsiderTrades – De Sousa sale

Afya Company Profile

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.